Posted by Michael Wonder on 09 Sep 2021
Albireo receives UK MHRA approval of Bylvay (odevixibat)
8 September 2021 - Bylvay now approved in U.S., EU and UK as first drug treatment for patients with progressive familial intrahepatic cholestasis.
Albireo Pharma today announced that the UK MHRA has granted marketing authorisation for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis.
